logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Incyte Corporation drugs

    FiltersReset Filters
    6 results

    • jakafi

      (ruxolitinib)
      Incyte Corporation
      Usage: Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.

    • monjuvi - tafasitamab - cxix injection, powder, lyophilized, for solution

      (Tafasitamab-Cxix)
      Incyte Corporation

    • niktimvo

      (axatilimab-csfr)
      Incyte Corporation
      Usage: NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, following the failure of at least two prior lines of systemic therapy.

    • opzelura

      (ruxolitinib)
      Incyte Corporation
      Usage: OPZELURA is indicated for the topical short-term treatment of mild to moderate atopic dermatitis in patients 12 years and older, and for nonsegmental vitiligo in adults and pediatric patients. It should not be used in combination with other JAK inhibitors or potent immunosuppressants.

    • pemazyre

      (pemigatinib)
      Incyte Corporation
      Usage: PEMAZYRE is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, and for adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

    • zynyz

      (retifanlimab-dlwr)
      Incyte Corporation
      Usage: ZYNYZ is indicated for treating adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Its approval is based on tumor response and duration, with ongoing validation of clinical benefit required from confirmatory trials.